Synthesis and antidiabetic activity of 3,6,7-trisubstituted-2-(1H-imidazol- 2-ylsulfanyl)quinoxalines and quinoxalin-2-yl isothioureas

Archiv der Pharmazie

Volumn 340, Issue 7, 2007, Pages 359-366

  Bahekar, Rajesh H ^a   Jain, Mukul R ^a   Gupta, Arun A ^a   Goel, Ashish ^a   Jadav, Pradip A ^a   Patel, Dipam N ^a   Prajapati, Vijay M ^a   Patel, Pankaj R ^a  

^a ZYDUS RESEARCH CENTRE   (India)

Author keywords

Antidiabetic; Imidazol 2 ylsulfanyl; Insulinotropic; Isothiourea; Quinoxaline

Indexed keywords

2 (1H IMIDAZOL 2 YLSULFANYL) 3 (TRIFLUORONETHYL)QUINOXALINE; 2 (1H IMIDAZOL 2 YLSULFANYL) 3 METHYLQUINOXALINE; 2 (1H IMIDAZOL 2 YLSULFANYL) 3 PHENYLQUINOXALINE; 2 (1H IMIDAZOL 2 YLSULFANYL)QUINOXALINE; 2 (3 (TRIFLUOROMETHYL)QUINOXALIN 2 YL)ISOTHIOUREA; 2 (3 METHYL QUINOXALIN 2 YL)ISOTHIOUREA; 2 (3 PHENYLQUINOXALIN 2 YL)ISOTHIOUREA; 2 (6,7 DICHLORO 3 (TRIFLUOROMETHYL)QUINOXALIN 2 YL)ISOTHIOUREA; 2 (6,7 DICHLORO 3 METHYLQUINOXALIN 2 YL)ISOTHIOUREA; 2 (6,7 DICHLORO 3 PHENYLQUINOXALIN 2 YL)ISOTHIOUREA; 2 (6,7 DICHLOROQUINOXALIN 2 YL)ISOTHIOUREA; 2 (7 CHLORO 3 (TRIFLUOROMETHYL)QUINOXALIN 2 YL)ISOTHIOUREA; 2 (7 CHLORO 3 METHYLQUINOXALIN 2 YL)ISOTHIOUREA; 2 (7 CHLORO 3 PHENYLQUINOXALIN 2 YL)ISOTHIOUREA; 2 (7 CHLOROQUINOXALIN 2 YL)ISOTHIOUREA; 2 QUINOXALINE 2 YLISOTHIOUREA; 6 CHLORO 3 (1H IMIDAZOL 2 YLSULFANYL) 2 (TRIFLUOROMETHYL)QUINOXALINE; 6 CHLORO 3 (1H IMIDAZOL 2 YLSULFANYL) 2 METHYLQUINOXALINE; 6 CHLORO 3 (1H IMIDAZOL 2 YLSULFANYL) 2 PHENYLQUINOXALINE; 6,7 DICHLORO 2 (1H IMIDAZOL 2 YLSULFANYL) 3 (TRIFLUOROMETHYL)QUINOXALINE; 6,7 DICHLORO 2 (1H IMIDAZOL 2 YLSULFANYL) 3 METHYLQUINOXALINE; 6,7 DICHLORO 2 (1H IMIDAZOL 2 YLSULFANYL)QUINOXALINE; 7 CHLORO 2 (1H IMIDAZOL 2 YLSULFANYL)QUINOXALINE; ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; INFRARED SPECTROSCOPY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INSULIN; INSULIN-SECRETING CELLS; QUINOXALINES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; THIOUREA;

EID: 34547227194     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700024     Document Type: Article

References (31)

1. S. E. Inzucchi, J. Am. Med. Assoc. 2002, 287, 360-372.
2. F. M. Ashcroft, Horm Metab. Res. 1996, 28, 456-463.
3. H. Sakura, C. Ammala, P. A. Smith, F. M. Gribble, F. M. Ashcroft, FEBS Lett. 1995, 377, 338-344.
4. N. Inagaki, T. Gonoi, J. P. Clement, N. Amba, et al., Science 1995, 270, 1166-1169.
5. E. F. Pfeiffer, C. Thum, S. Raptis, W. Beischer, R. Ziegler, Horm. Metab. Res. 1976, Suppl. 6, 112-126.
6. L. C. Groop, Diabetes Care 1992, 15, 737-754.
7. T. J. Kieffer, J. F. Habener, Endocr. Rev. 1999, 20, 876-913.
8. L. L. Nielsen, A. A. Young, D. G. Parkes, Regul. Pept. 2004, 117, 77-88.
9. M. A. Nauck, M. M. Heimesaat, C. Orskov, J. J. Holst, et al., J. Clin. Invest 1993, 91, 301-307.
10. A. A. Young, B. R. Gedulin, T. J. Rink, Metabolism 1996, 45, 1-3.
11. H. R. Davis, D. E. Mullins, J. M. Pines, L. M. Hoos, et al., Obes. Res. 1998, 6, 147-156.
12. R. Perfetti, J. Zhou, M. E. Doyle, J. M. Egan, Endocrinology 2000, 141, 4600-4605.
13. B. Thorens, A. Porret, L. Buhler, S. P. Deng, et al., Diabetes 1993, 42, 1678-1682.
14. S. Runge, B. S. Wulff, K. Madsen, H. Bruner-Osborne, L. B. Knudsen, Br. J. Pharmacol. 2003, 138, 787-794.
15. K. E. Mayo, L. J. Miler, D. Bataille, S. Dalle, et al., Pharmacol. Rev. 2003, 55, 167-194.
16. G. G. Holz, C. A. Leech, J. F. Habner, Biochimie 2000, 82, 915-926.
17. D. K. Arulmozhi, B. Portha, Eur. J. Pharm. Sci. 2006, 28, 96-108.
18. L. B Knudsen, P. F. Nielsen, P. O. Huusfeldt, N. L. Johansen, et al., J. Med. Chem. 2000, 43, 1664-1669.
19. L. B. Knudson, H. Agerso, C. Bjenning, S. Bregenholt, et al., Drugs of the future 2001, 26, 677-685.
20. J. Larsen, B. Hylleberg, K. Ng, P. Damsbo, Diabetes Care 2001, 24, 1416-1421.
21. T. H. Ji, M. Grossmann, I. Ji, J. Biol. Chem. 1998, 273, 17299-17302.
22. S. R. J. Haore, Drug Discov. Today 2005, 10, 417-424.
23. L. B. Knudsen, D. Kiel, M. Teng, C. Behrens, et al., Proc. Natl. Acad. Sci. USA 2007, 104, 937-942.
24. D. J. D. Hockenhull, G. D. Floodgate, Biochem. J. 1952, 52, 3840.
25. M. Teng, K. L. Truesdale, D. Bhumralkar, M. D.Johnson, et al., (Novo Nordisk) WO 0042026, 2000.
26. H. Masatoshi, Y. Sadakazu, H. Katsuo, S. Kaoru (Taisho Pharmaceutical) JP62187469 A2, 1987.
27. K. J. Doebel, A. R. Gagneux (Geigy Chemical Corporation) US 3636003, 1972.
28. C. M. Rafizadeh, H. Yang, B. D. Rodgers, A. Beday, et al., J. Biol. Chem. 1997, 272, 21201-21206.
29. R. Golla, R. Seethala, J. Biomol. Screening 2002, 7, 515-525.
30. C. Montrose-Rafizadeh, Y. Wang, T. E. Janczewski, T. E. Henderson, J. M. Egan, Mol. Cell. Endo. 1997, 130, 109-117.
31. X. Wang, J. Zhou, M. E. Doyle, J. M. Egan, Endocrinology 2001, 5, 1820-1827.